Areas covered: This review will focus on the new options for combination therapies, which have already recently arrived or are going to arrive in the clinical practice, mainly through registrative trials, for the management of advanced nonsquamous non oncogene-addicted NSCLC. A structured search of...
Few standard treatments have been available for advanced myelofibrosis, a bone marrow disorder characterized by excessive scar tissue that disrupts the normal production of blood cells But new research conducted by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller Scho...
Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET) Medulloblastoma and central nervous system (CNS) primitive neuroectodermal tumor (PNET) are primary pediatric brain tumors that require multidisciplinary t... KC De Braganca,RJ Packer - 《Curr Treat Options Neurol》 被...
Dec. 11, 2002 — Two presentations at the 25th Annual San Antonio Breast Cancer Symposium on Dec. 11 suggest new treatment options in advanced breast cancer refractory to conventional chemotherapy. A double-blind crossover trial showed that anastrozole (ARI) should be given as first-line adjuvant...
Treatment options for hearing loss are mostly based on medical devices, including hearing aids and cochlear implants; there are no pharmacological therapeutics currently in widespread use. Hair cells in the inner ear are the sensory cells for the detection of sound; hair cells are frequently affected...
Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, partic...
New Options for Metastatic Breast Cancer Patients with advanced breast cancer are living longer and receiving multiple lines of chemotherapy; however, they eventually develop resistance to the age... DK Frye,SM Mahon,FM Palmieri - 《Clinical Journal of Oncology Nursing》 被引量: 28发表: 2009年 ...
The mainstays of treatment for early stage disease are either radiotherapy or surgery. However, although disease responds well at this stage, the risk of a second primary cancer is high, with a development rate of about 4% per year. Advanced diseases are treated either by surgery with ...
(Yun et al.2020). The tyrosine kinase inhibitorrepotrectinibwas approved for locally advanced or metastatic ROS1-positive NSCLC. Repotrectinib received priority review, breakthrough, and fast track designation. The most common AE are dizziness, taste disorder, peripheral neuropathy, constipation, ...
这项研究证明了TAK-228抑制剂在NRF2激活的肺鳞癌细胞中的效果,并在NFE2L2突变的晚期肺鳞癌患者中验证这一效果。该试验是NSCLC代谢靶向治疗的第一次成功尝试,并且可以说是迄今为止对肺鳞癌患者最有前途的靶向治疗方法。 参考文献 1. Socinski M...